Want to see GALT full AI Analyst Report?
Total Valuation
Galectin Therapeutics has a market cap or net worth of $305.58M. The enterprise value is $304.03M.
Market Cap$305.58M
Enterprise Value$304.03M
Share Statistics
Galectin Therapeutics has 65,856,895 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding65,856,895
Owned by Insiders26.04%
Owned by Institutions4.52%
Financial Efficiency
Galectin Therapeutics’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is -174.29%.
Return on Equity (ROE)0.24
Return on Assets (ROA)-1.58
Return on Invested Capital (ROIC)-174.29%
Return on Capital Employed (ROCE)-1.75
Revenue Per Employee0.00
Profits Per Employee-2.06M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Galectin Therapeutics is ―. Galectin Therapeutics’s PEG ratio is 0.24.
PE Ratio―
PS Ratio0.00
PB Ratio-2.11
Price to Fair Value-2.11
Price to FCF-11.13
Price to Operating Cash Flow―
PEG Ratio0.24
Income Statement
In the last 12 months, Galectin Therapeutics had revenue of 0.00 and earned -30.84M in profits. Earnings per share was -0.48.
Revenue0.00
Gross Profit0.00
Operating Income-20.09M
Pretax Income-30.84M
Net Income-30.84M
EBITDA-23.45M
Earnings Per Share (EPS)-0.48
Cash Flow
In the last 12 months, operating cash flow was -23.88M and capital expenditures 0.00, giving a free cash flow of -23.88M billion.
Operating Cash Flow-23.88M
Free Cash Flow-23.88M
Free Cash Flow per Share-0.36
Dividends & Yields
Galectin Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.48
52-Week Price Change109.01%
50-Day Moving Average2.63
200-Day Moving Average3.72
Relative Strength Index (RSI)77.80
Average Volume (3m)331.12K
Important Dates
Galectin Therapeutics upcoming earnings date is Aug 17, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Galectin Therapeutics as a current ratio of 2.42, with Debt / Equity ratio of ―
Current Ratio2.42
Quick Ratio2.42
Debt to Market Cap0.50
Net Debt to EBITDA-4.95
Interest Coverage Ratio-2.74
Taxes
In the past 12 months, Galectin Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Galectin Therapeutics EV to EBITDA ratio is -16.28, with an EV/FCF ratio of -15.99.
EV to Sales0.00
EV to EBITDA-16.28
EV to Free Cash Flow-15.99
EV to Operating Cash Flow-15.99
Balance Sheet
Galectin Therapeutics has $17.72M in cash and marketable securities with $135.72M in debt, giving a net cash position of -$116.04M billion.
Cash & Marketable Securities$17.72M
Total Debt$135.72M
Net Cash-$116.04M
Net Cash Per Share-$1.76
Tangible Book Value Per Share-$1.97
Margins
Gross margin is ―, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin―
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Galectin Therapeutics is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.00
Price Target Upside92.64% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast43.38%